

*REMARKS*

*The Present Invention*

The present invention pertains to isolated immunogenic peptides, single-chain Class II-MHC-peptide constructs, compositions, derivatives of the immunogenic peptides, and methods of inducing CD4<sup>+</sup> T lymphocytes.

*The Pending Claims*

Upon entry of this amendment, claims 100, 107-137, and 192-220 will be pending. Claims 100 and 107-113 are directed to isolated immunogenic peptides. Claims 192-194 are directed to derivatives of an isolated immunogenic peptide. Claims 114, 115, 195, and 196 are directed to single-chain Class II-MHC-peptide constructs. Claims 116, 117, 197, and 198 are directed to compositions comprising the immunogenic peptides or derivatives thereof, and claims 118-137 and 199-218 are directed to methods of using the compositions.

*Amendments to the Claims*

Typographical errors in claims 195, 198, 219, and 220 have been amended. Specifically, the hyphen between "peptide-construct" has been deleted in claim 195. In claim 198, the term "is" has been deleted. In claims 219 and 220, the first letters of each word of the phrase "major histocompatibility complex (MHC) class II" has been capitalized. No new matter has been entered by way of these amendments.

*Conclusion*

The application is considered in good and proper form for allowance, and should not be withdrawn from issue. If, in the opinion of the

In re Appln. of Topalian et al.  
Application No. 08/533,895

Examiner, a telephone conference would expedite the prosecution of the subject application,  
the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



---

David J. Schodin, Reg. No. 41,294  
LEYDIG, VOIT & MAYER, LTD.  
Two Prudential Plaza, Suite 4900  
180 North Stetson Avenue  
Chicago, Illinois 60601-6780  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

Date: September 8, 2004

*m:\Clients\nih\amd219490 and under 1.312.doc*